Response

In the early 1990s, a series of randomized trials demonstrated the efficacy of both pharmaceutical aids with behavioral therapy for smoking cessation and treatments for metastatic breast cancer. These treatments were approved by the US Food and Drug Administration and quickly disseminated into clinical practice. A decade later, the population mean survival following a metastatic breast cancer diagnosis had improved 50%, demonstrating the effectiveness of the treatment (1); however, there was no improvement in the proportion of smokers who had successfully quit (2). A critical public health question is how to account for the apparent lack of translation of quitting success into the population.

http://ift.tt/2EZviQV